
|Articles|May 1, 2005
Macular edema device coming to Japan
Irvine, CA—Allergan Inc. has signed an exclusive licensing agreement with Japan's Sanwa Kagaku Kenkyusho Co. Ltd. to develop and commercialize Posurdex for the ophthalmic marketplace in that country.
Advertisement
Irvine, CA-Allergan Inc. has signed an exclusive licensing agreement with Japan's Sanwa Kagaku Kenkyusho Co. Ltd. to develop and commercialize Posurdex for the ophthalmic marketplace in that country.
The investigational, bioerodable, extended release implant is designed to deliver dexamethasone to the back of the eye to treat macular edema. The companies estimate Japan's annual macular edema market at more than $100 million.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
Study links alcohol consumption to earlier advanced presbyopia in men
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















